Health Minister Hsueh Jui-yuan (薛瑞元) said Wednesday the ministry's commissioning of Choice Pharma Taiwan to conduct Phase 2 clinical trials of the locally manufactured Medigen COVID-19 vaccine predated a merger between Choice Pharma's parent company and a Shanghai-based firm, amid controversy over possible Chinese involvement in the trials.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Society
Labor ministry updates rules expanding shutdowns after work accidents
07/08/2025 11:01 PM - Business
Taiwan's consumer price index eases to 1.37%, a 4-year low: DGBAS
07/08/2025 10:36 PM - Society
2 dead after dinghy capsizes in New Taipei rescue mission
07/08/2025 10:12 PM - Business
Taiwan's exports rise for 20th straight month to new high in June
07/08/2025 09:53 PM - Cross-Strait
CAA addresses Chinese civilian plane flying over Kinmen
07/08/2025 09:27 PM